Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-13T01:04:14.316Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae

Published online by Cambridge University Press:  05 April 2018

Oded Scheuerman ,
Vered Schechner ,
Yehuda Carmeli ,
Belen Gutiérrez-Gutiérrez ,
Esther Calbo ,
Benito Almirante ,
Pier-Luigy Viale ,
Antonio Oliver ,
Patricia Ruiz-Garbajosa  and
Oriol Gasch
...Show all authors
Oded Scheuerman*
Affiliation:
Division of Epidemiology and Preventive Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel National Center for Infection Control, Israel Ministry of Health, Tel Aviv, Israel Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Vered Schechner
Affiliation:
Division of Epidemiology and Preventive Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel National Center for Infection Control, Israel Ministry of Health, Tel Aviv, Israel Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Yehuda Carmeli
Affiliation:
Division of Epidemiology and Preventive Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel National Center for Infection Control, Israel Ministry of Health, Tel Aviv, Israel Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Belen Gutiérrez-Gutiérrez
Affiliation:
Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Seville, Spain Instituto de Biomedicina de Sevilla, Universidad de Sevilla, Seville, Spain
Esther Calbo
Affiliation:
Hospital Universitari Mútua de Terrassa, Barcelona, Spain
Benito Almirante
Affiliation:
Hospital Universitari Vall d’Hebrón, Barcelona, Spain
Pier-Luigy Viale
Affiliation:
Teaching Hospital Policlinico S. Orsola Malpighi, Bologna, Italy
Antonio Oliver
Affiliation:
Hospital Universitario Son Espases, Palma de Mallorca, Spain
Patricia Ruiz-Garbajosa
Affiliation:
Hospital Ramón y Cajal, Madrid, Spain
Oriol Gasch
Affiliation:
Corporacio Sanitaria Parc Taulí, Sabadell, Barcelona, Spain
Monica Gozalo
Affiliation:
Hospital Universitario Marqués de Valdecilla—IDIVAL, Santander, Spain
Johann Pitout
Affiliation:
Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada
Murat Akova
Affiliation:
Hacettepe University School of Medicine, Ankara, Turkey
Carmen Peña
Affiliation:
Hospital Universitari de Bellvitge, Barcelona, Spain
Jose Molina
Affiliation:
Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocio, CSIC, University of Seville, Seville, Spain
Alicia Hernández-Torres
Affiliation:
Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
Mario Venditti
Affiliation:
Policlinico Umberto I, University of Rome La Sapienza, Rome, Italy
Nuria Prim
Affiliation:
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Julia Origüen
Affiliation:
Hospital Universitario 12 de Octubre, Madrid, Spain
German Bou
Affiliation:
Complejo Hospitalario Universitario A Coruña, A Coruña, Spain
Evelina Tacconelli
Affiliation:
Universitätsklinikum Tübingen, Tübingen, Germany
Maria Tumbarello
Affiliation:
Catholic University of the Sacred Heart, Rome, Italy
Axel Hamprecht
Affiliation:
Institut für Mikrobiologie, Immunologie und Hygiene Universitätsklinikum Köln, Cologne, Germany
Ilias Karaiskos
Affiliation:
Hygeia General Hospital, Athens,Greece
Cristina de la Calle
Affiliation:
Hospital Clinic, Barcelona, Spain
Federico Pérez
Affiliation:
Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, United States
Mitchell J. Schwaber
Affiliation:
Division of Epidemiology and Preventive Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel National Center for Infection Control, Israel Ministry of Health, Tel Aviv, Israel Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Joaquin Bermejo
Affiliation:
Hospital Español, Rosario, Argentina
Warren Lowman
Affiliation:
Wits Donald Gordon Medical Centre, Johannesburg, South Africa
Po-Ren Hsueh
Affiliation:
National Taiwan University Hospital, National Taiwan University Hospital College of Medicine, Taipei, Taiwan
Carolina Navarro-San Francisco
Affiliation:
Hospital Universitario La Paz, Madrid, Spain
Robert A. Bonomo
Affiliation:
Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, United States Departments of Medicine, Pharmacology, Biochemistry, Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States
David L. Paterson
Affiliation:
University of Queensland Centre for Clinical Research, The University of Queensland, Herston, Brisbane, Australia
Alvaro Pascual
Affiliation:
Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Seville, Spain Instituto de Biomedicina de Sevilla, Universidad de Sevilla, Seville, Spain
Jesus Rodríguez-Baño
Affiliation:
Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Seville, Spain Instituto de Biomedicina de Sevilla, Universidad de Sevilla, Seville, Spain
*
Address correspondence to O. Scheuerman, MD, Division of Epidemiology and Preventive Medicine, Tel Aviv Sourasky Medical Center Tel Aviv and Schneider Children’s Medical Center of Israel, Petach Tikva 4920235, Israel (odedshv@clalit.org.il).
Get access Rights & Permissions [Opens in a new window]

Abstract

OBJECTIVE

To compare the epidemiology, clinical characteristics, and mortality of patients with bloodstream infections (BSI) caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (ESBL-EC) versus ESBL-producing Klebsiella pneumoniae (ESBL-KP) and to examine the differences in clinical characteristics and outcome between BSIs caused by isolates with CTX-M versus other ESBL genotypes

METHODS

As part of the INCREMENT project, 33 tertiary hospitals in 12 countries retrospectively collected data on adult patients diagnosed with ESBL-EC BSI or ESBL-KP BSI between 2004 and 2013. Risk factors for ESBL-EC versus ESBL-KP BSI and for 30-day mortality were examined by bivariate analysis followed by multivariable logistic regression.

RESULTS

The study included 909 patients: 687 with ESBL-EC BSI and 222 with ESBL-KP BSI. ESBL genotype by polymerase chain reaction amplification of 286 isolates was available. ESBL-KP BSI was associated with intensive care unit admission, cardiovascular and neurological comorbidities, length of stay to bacteremia >14 days from admission, and a nonurinary source. Overall, 30-day mortality was significantly higher in patients with ESBL-KP BSI than ESBL-EC BSI (33.7% vs 17.4%; odds ratio, 1.64; P=.016). CTX-M was the most prevalent ESBL subtype identified (218 of 286 polymerase chain reaction-tested isolates, 76%). No differences in clinical characteristics or in mortality between CTX-M and non–CTX-M ESBLs were detected.

CONCLUSIONS

Clinical characteristics and risk of mortality differ significantly between ESBL-EC and ESBL-KP BSI. Therefore, all ESBL-producing Enterobacteriaceae should not be considered a homogeneous group. No differences in outcomes between genotypes were detected.

CLINICAL TRIALS IDENTIFIER

ClinicalTrials.gov. Identifier: NCT01764490.

Infect Control Hosp Epidemiol 2018;39:660–667

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 39 , Issue 6 , June 2018 , pp. 660 - 667
Copyright
© 2018 by The Society for Healthcare Epidemiology of America. All rights reserved 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

a

Other investigators in the REIPI/ESGBIS/INCREMENT project: J. Guzmán Puche, University General Hospital Attikoni, Greece; M. Souli, Case Western Reserve University School of Medicine, Cleveland Ohio, United States; J. Gálvez, Hospital Universitario Virgen Macarena, Seville, Spain; M. Falcone and A. Russo, Policlinico Umberto I, Rome, Italy; G. Daikos, Laikon General Hospital, Athens, Greece; E. M. Trecarichi and A. R. Losito, Catholic University of the Sacred Heart, Rome, Italy; J. Gómez and E. García-Vázquez, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; E. Iosifidis and E. Roilides, Hippokration Hospital of Thessaloniki, Thessaloniki, Greece; I. Karaiskos, Hygeia General Hospital, Athens, Greece; Y. Doi, University of Pittsburgh, Pittsburgh, Pennsylvania, United States; F. F. Tuon, Hospital da Universidade Federal do Paraná, Paraná, Brazil; J. A. Martínez, L. Morata and A. Soriano, Hospital Clinic, Barcelona, Spain; F. Navarro and B. Mirelis, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; R. San Juan and M. Fernández-Ruiz, Hospital 12 de Octubre, Madrid, Spain; N. Larrosa and M. Puig, Hospital Universitario Vall d’Hebrón, Barcelona, Spain; J. Molina and V. González, Hospital Universitario Virgen del Rocío, Seville, Spain; V. Rucci, Hospital Español, Rosario, Argentina; E. Ruiz de Gopegui and C. I. Marinescu, Hospital Universitario Son Espases, Palma de Mallorca, Spain; M. C. Fariñas, M. E. Cano, and M. Gozalo, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain; J. R. Paño-Pardo and Marta Mora-Rillo, Hospital Universitario La Paz-IDIPAZ, Madrid, Spain; S. Gómez-Zorrilla and F. Tubau, Hospital de Bellvitge, Barcelona, Spain; S. Pournaras, A. Tsakris, and O. Zarkotou, University of Athens, Athens, Greece; Ö. K. Azap, Baskent University, Ankara, Turkey; M. Souli, A. Antoniadou, and G. Poulakou, University General Hospital Attikon, Chiadiri, Greece; D. Virmani, University of Calgary, Calgary, Canada; Á. Cano and J. Guzmán-Puche, Hospital Universitario Reina Sofía-IMIBIC, Córdoba, Spain; Ö. Helvaci and A. O. Sahin, Hacettepe University, Ankara, Turkey; V. Pintado and R. Cantón, Hospital Ramón y Cajal, Madrid, Spain; M. Bartoletti and M. Giannella, Teaching Hospital Policlinico S. Orsola Malpighi, Bologna, Italy; S. Peter, Tübingen University Hospital, Tübingen, Germany; C. Badia and M. Xercavins, Hospital Universitario Mútua de Terrassa, Terrassa, Spain; D. Fontanals and E. Jové, Hospital Parc Taulí, Sabadell, Spain.

References

REFERENCES

1. Morrissey, I, Hackel, M, Badal, R, Bouchillon, S, Hawser, S, Biedenbach, D. A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel) 2013;6:1335–1346.Google Scholar
2. Martelius, T, Jalava, J, Kärki, T, Möttönen, T, Ollgren, J, Lyytikäinen, O. Nosocomial bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae resistant to third-generation cephalosporins, Finland, 1999–2013: Trends, patient characteristics and mortality. Infect Dis (Lond) 2016;48:229–234.CrossRefGoogle ScholarPubMed
3. Castanheira, M, Farrell, SE, Krause, KM, Jones, RN, Sader, HS. Contemporary diversity of beta-lactamases among Enterobacteriaceae in the nine US census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent beta-lactamase groups. Antimicrob Agents Chemother 2014;58:833–838.CrossRefGoogle ScholarPubMed
4. Ben-Ami, R, Schwaber, MJ, Nanon-Venezia, S, et al. Influx of extended-spectrum beta-lactamase-producing Enterobacteriaceae into the hospital. Clin Infect Dis 2006;42:925–934.CrossRefGoogle ScholarPubMed
5. Burwen, DR, Banerjee, SN, Gaynes, RP. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. National Nosocomial Infections Surveillance System. J Infect Dis 1994;179:1622–1625.CrossRefGoogle Scholar
6. Canton, R, Coque, TM. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol 2006;9:466–475.CrossRefGoogle ScholarPubMed
7. Schwaber, MJ, Carmeli, Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007;60:913–920.CrossRefGoogle ScholarPubMed
8. Tacconelli, E, Cataldo, MA, Dancer, SJ, et al. European Society of Clinical Microbiology. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant gram-negative bacteria in hospitalized patients. Clin Microbiol Infect 2014;20(Suppl 1):1–55.CrossRefGoogle ScholarPubMed
9. Rodríguez-Baño, J, Navarro, MD, Retamar, P, Picón, E, Pascual, Á. Extended-Spectrum Beta-Lactamases–Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012;54:167–174.Google ScholarPubMed
10. Charlson, ME, Pompei, P, Ales, KL, MacKenzie, CR. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.CrossRefGoogle ScholarPubMed
11. McCabe, WR, Jackson, GG. Gram-negative bacteremia. Etiology and ecology. Arch lntern Med 1962;110:845–855.Google Scholar
12. Hilf, M, Yu, Vh, Sharp, J, Zuravleff, JJ, Korvick, JA, Muder, RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989;87:540–546.CrossRefGoogle Scholar
13. Garner, JS, Jarvis, WR, Emori, TG, Horan, TC, Hughes, JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128–140.CrossRefGoogle ScholarPubMed
14. Clinical and laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Second Informational Supplement. CLSI document M100-S22. Wayne, PA: Clinical and laboratory Standards Institute; 2012.Google Scholar
15. Freeman, JT, Rubin, J, McAuliffe, GN, et al. Differences in risk-factor profiles between patients with ESBL-producing Escherichia coli and Klebsiella pneumoniae: a multicentre case-case comparison study. Antimicrob Resist Infect Control 2014;3:27.CrossRefGoogle ScholarPubMed
16. Sakellariou, C, Gürntke, S, Steinmetz, I, et al. Sepsis caused by extended-spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: comparison of severity of sepsis, delay of anti-infective therapy and ESBL Genotype. PLoS One 2016;11:e0158039.CrossRefGoogle Scholar
17. Xia, S, Fan, X, Huang, Z, et al. Dominance of CTX-M-type extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli isolated from patients with community-onset and hospital-onset infection in China. PLoS One 2014;9:e100707.CrossRefGoogle ScholarPubMed
18. Gürntke, S, Kohler, C, Steinmetz, I, et al. Molecular epidemiology of extended-spectrum beta-lactamase (ESBL)-positive Klebsiella pneumoniae from bloodstream infections and risk factors for mortality. J Infect Chemother 2014;20:817–819.CrossRefGoogle ScholarPubMed
Supplementary material: File

Scheuerman et al. supplementary material

Table S1

Download Scheuerman et al. supplementary material(File)
File 30 KB